Clozapine-induced Hypersalivation - Feasibility Trial (GOTHIC1)
A Feasibility Study of Glycopyrrolate in Comparison to Hyoscine Hydrobromide and Placebo in the Treatment of Hypersalivation Induced by Clozapine
Sponsor: Lancashire Care NHS Foundation Trust
Listed as NCT02613494, this PHASE1/PHASE2 trial focuses on Sialorrhea and remains completed. Sponsored by Lancashire Care NHS Foundation Trust, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
Feb 2018 — Mar 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lancashire Care NHS Foundation Trust
- Manchester Mental Health & Social Care Trust
- Mersey Care NHS Trust
- University of Central Lancashire
- University of Manchester
For direct contact, visit the study record on ClinicalTrials.gov .